| Name | Title | Contact Details |
|---|
With iCAD`s technology, cancer has finally met its match. As a global medical technology leader providing innovative cancer detection and therapy solutions, our technologies empower clinicians worldwide with an arsenal of tools to detect cancer and stop it in its tracks – streamlining workflow, improving accuracy, and personalizing results like never before. The ProFound AI Breast Health Suite is the first, best, and only complete, triple-threat solution that combines cancer detection, density assessment, and risk evaluation – all designed to accelerate discovery and improve outcomes. Our leading-edge cancer detection solution, ProFound AI®, is clinically proven to find cancers earlier and with greater accuracy, while slashing reading time for radiologists by more than half. PowerLook® Density Assessment simplifies and standardizes breast density reporting and stratification, offering consistent, accurate and reliable breast density categorization. And the latest addition to our Breast AI Suite, ProFound AI® Risk, is the world`s first clinical decision support tool that provides an accurate short-term breast cancer risk estimation that is truly personalized for each woman, based only on her mammogram. Our Xoft® Axxent® Electronic Brachytherapy (eBx®) System® is transforming the cancer treatment experience by empowering physicians to precisely and effectively target tumors anywhere in the body, anywhere in the world. Using the world`s smallest X-ray source, clinicians can precisely destroy disease while preserving healthy tissue, leaving cancer nowhere to hide.
Medacta International is a Swiss company developing, manufacturing and distributing orthopaedic and neurosurgical medical devices worldwide. Founded in 1999 with a vision to create a better patient experience for people needing joint and spine treatment, Medacta specializes in highly innovative minimally-invasive, personalized approaches designed to bring renewed hope and optimism to patients. Medacta is a recognized leader in Hip Replacement with its proprietary AMIS® (Anterior Minimally Invasive Surgery) product offerings and in Knee Replacement via MyKnee® Patient Matched 3-D printing technology. At the 2014 North American Spine Society (NASS) Annual Meeting, Medacta`s new MySpine® Patient Matched product was awarded "Best New Technology - Posterior Thoracolumbar Spine Treatments".
OrbusNeich is a Fort Lauderdale, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Neogen Corporation (Neogen), together with its subsidiaries, develops, manufactures and markets a line of products dedicated to food and animal safety.
American Diagnostic Corporation is a Hauppauge, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.